2 assets in Mucinous Ovarian Cancer

Therapeutic assets addressing Mucinous Ovarian Cancer, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Avutometinib Mucinous Ovarian Cancer	University of Oklahoma	P2	CCC (53)
Defactinib Mucinous Ovarian Cancer	University of Oklahoma	P2	CCC (53)